Ozempic-maker's shares plunge after failed Alzheimer's trial
Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer's disease.
The discount retailer B&M has seen its market value plunge by almost a fifth after a downgrade of up to £40m in annual profit expectations due to an accounting blunder.
Elon Musk and the OpenAI boss have spent the last three weeks battling in court over Sam Altman's company, in a trial that could mould the future of artificial intelligence.
We process personal data about users of our site, through the use of cookies and other technologies, to deliver our services, personalize advertising, and to analyze site activity. We may share certain information about our users with our advertising and analytics partners. For additional details, refer to our Privacy Policy.
By clicking "I AGREE" below, you agree to our Privacy Policy and our personal data processing and cookie practices as described therein. You also acknowledge that this forum may be hosted outside your country and you consent to the collection, storage, and processing of your data in the country where this forum is hosted.